A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease

2016 ◽  
Vol 54 (4) ◽  
pp. 1509-1519 ◽  
Author(s):  
Mark Brody ◽  
Enchi Liu ◽  
Jianing Di ◽  
Ming Lu ◽  
Richard A. Margolin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Phase Ii ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

2012 ◽  
Vol 4 (5) ◽  
pp. 43 ◽  
Author(s):  
John M Ringman ◽  
Sally A Frautschy ◽  
Edmond Teng ◽  
Aynun N Begum ◽  
Jenny Bardens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study

Neurology ◽  
2003 ◽  
Vol 60 (7) ◽  
pp. 1071-1076 ◽  
Author(s):  
O.M. Wolkowitz ◽  
J.H. Kramer ◽  
V.I. Reus ◽  
M.M. Costa ◽  
K. Yaffe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dhea Treatment
Sign in / Sign up

Export Citation Format

Share Document